Daily Bio News Summary — 2026-09-20

Today’s harvest produced a small, tight batch: four items from the FDAbisector feed, two of them regulatory milestones for small private companies and two covering clinical leadership and preclinical data. As the sections below explain, the size of the batch is not a quiet-news signal — it is the result of four consecutive days of sweeping the same eleven homepages, where nearly every trade-press headline now matches a file the collection already holds.

Regulatory: an inhaled cell therapy clears its first U.S. hurdle

The lead item is SMSbiotech’s disclosure that the FDA allowed its investigational new drug application to proceed for inhaled allogeneic SMS Cells in chronic obstructive pulmonary disease (PR Newswire FDA, 2026-09-16). According to the release, the company frames this as the first U.S. IND-cleared inhaled stem cell therapy in COPD, with the IND effective after the FDA’s 30-day review and a Phase 1b trial targeted to begin in the fourth quarter of 2026. The program’s delivery route — nebulized inhalation of an off-the-shelf, refrigerated cell product — is the differentiating claim, and the release also notes that an ongoing Australian Phase 1b COPD study has completed the first of three cohorts.

The same day brought a device-side equivalent: KELLS reported that its AI Dental Scan was registered as a Class B medical device with Singapore’s Health Sciences Authority (PR Newswire FDA, 2026-09-16). The company’s framing is that this makes it Singapore’s first HSA-registered AI dental screening tool intended for direct consumer use — a smartphone-camera screening product rather than a clinical-grade imaging system — with the registration positioned as a validation step for its expansion in that market.

Clinical leadership: Olatec builds out around a Phase 2 Parkinson’s program

Olatec Therapeutics announced two additions to its clinical leadership (PR Newswire FDA, 2026-09-15): Caroline Williams-Gray, FRCP PhD, to its Clinical Advisory Board, and David Haase, MD, to both its Board of Directors and Clinical Advisory Board. The release ties the Williams-Gray appointment to an existing collaboration on Olatec’s Parkinson’s disease program — she is named as chief investigator for the Phase 2 DAPA-PD trial of dapansutrile in early Parkinson’s disease, which the release describes as enrolling. For a company whose platform is an oral NLRP3 inflammasome inhibitor, the significance is the continued investment in the Parkinson’s indication rather than the appointments themselves.

Preclinical: Acurx pushes in vitro data ahead of a co-culture problem

Acurx Pharmaceuticals said a scientific poster presented at the International C. difficile Symposium showed superior in vitro kill kinetics for ibezapolstat versus vancomycin and fidaxomicin in Clostridioides difficile and vancomycin-resistant Enterococcus co-cultures (PR Newswire FDA, 2026-09-14). The company’s stated takeaway is that the presence of Enterococcus creates a protective microenvironment that impairs standard-of-care killing — a mechanism claim, made in vitro, and one that would need clinical corroboration before it says anything about outcomes in recurrent CDI.

What this batch is NOT telling us

Four items, all from a single source, means several of the collection’s usual beats are simply absent today rather than quiet:

• No FDA Newsroom items. The agency’s newsroom parsed cleanly but produced nothing new — its recent items are already in the collection.
• No deal or financing news. No M&A, licensing, or IPO items cleared today, after a stretch in which the collection logged several.
• No trade-press stories. Nothing from Endpoints News, BioSpace, Fierce Pharma, Fierce Biotech, or STAT News survived adjudication today. The headlines those homepages are still carrying (a Novo rebrand, a CHMP round, a Lilly oral SERD approval, Ultragenyx’s gene therapy approval, Novartis’ Sironax acquisition) are all already represented in the collection.
• No AI-in-bio or public-market items.
• Nothing from BioPharma Dive or Reuters Biopharma, which both parsed zero items today. In Reuters’ case the homepage returned a bot interstitial rather than the article list, a recurring condition rather than a parser failure.

Reading order

1. SMSbiotech / COPD IND — the only item today with a first-in-class regulatory claim attached.
2. KELLS / Singapore HSA — the only device-registration item, and a rare non-U.S. regulatory milestone.
3. Olatec / DAPA-PD — read it for the ongoing Phase 2 Parkinson’s trial, not for the appointments.
4. Acurx / in vitro co-culture data — lowest signal-to-noise today; mechanism only.

How to read the underlying articles

Each item above corresponds to one markdown file in src/content/news/, and each file carries a sourceUrl field pointing at the original release. The descriptions in this post are drawn from those frontmatter fields and the linked releases — no figures, quotes, or readouts beyond them have been added. If a claim here matters to a decision, follow the source link; the release is the primary record.

Today’s items

1. SMSbiotech Receives FDA “Study May Proceed” Notification for First U.S. IND-Cleared Inhaled Stem Cell Therapy in COPD — PR Newswire FDA, 2026-09-16
2. KELLS AI Dental Scan Registered as Class B Medical Device with Singapore HSA — PR Newswire FDA, 2026-09-16
3. Olatec Therapeutics Appoints Parkinson’s Disease Investigator Caroline Williams-Gray, FRCP PhD, to Clinical Advisory Board and Physician-Innovator David Haase, MD, to Board of Directors — PR Newswire FDA, 2026-09-15
4. Acurx Announces Presentation of a Scientific Poster at the International C. difficile Symposium on Ibezapolstat Kill Kinetics — PR Newswire FDA, 2026-09-14